Adding Vandetanib to Platinum + Etoposide Not Effective for SCLC

Adding Vandetanib to Platinum + Etoposide Not Effective for SCLC
Adding Vandetanib to Platinum + Etoposide Not Effective for SCLC

The addition of vandetanib to a platinum agent and etoposide did not improve time to progression or overall survival in patients with newly diagnosed extensive-stage small cell lung cancer (SCLC), a study published in the journal Cancer has shown.1

Vandetanib is a kinase inhibitor of VEGFR, EGFR, and the RET-tyrosine kinase approved for the treatment of metastatic medullary thyroid cancer. Researchers hypothesized that angiogenesis inhibition by adding vandetanib to chemotherapy may improve clinical outcomes for patients with extensive-stage SCLC.

For the double-blind, phase 2 trial, investigators enrolled 66 patients with previously untreated disease and randomly assigned them 1:1 to receive cisplatin/carboplatin plus etoposide with vandetanib or placebo. Patients were treated for up to 4 cycles and did not receive maintenance therapy.

Median time to progression among evaluable patients was 5.62 months with vandetanib, etoposide, and a platinum compared with 5.68 months with chemotherapy and placebo (P =.9518).

Median overall survival was 13.24 months and 9.24 with vandetanib and placebo, respectively (P =.4577). There was also no significant difference in response rate or disease-control rate between the 2 treatment arms.

In terms of safety, patients treated with vandetanib reported higher rates of nonhematologic toxicity.

The study further revealed no association between VEGF polymorphisms and clinical outcomes.

Ultimately, these findings do not support continued investigation of vandetanib in an unselected population of patients with extensive SCLC.


1. Sanborn RE, Patel JD, Masters GA, et al. A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113. Cancer. 2016 Sep 1. doi: 10.1002/cncr.30287. [Epub ahead of print]

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs